Mechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells

20Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Colon cancer is a leading cause of morbidity and mortality in Western countries. Basic fibroblast growth factor (bFGF) was up-regulated in patients with colon cancer and was considered as a potential therapeutic target. In this study, we first demonstrated that a novel bFGF-binding peptide (named P7) inhibited proliferation of several colon cancer cell lines including HT-29, LoVo, and Caco2 cells stimulated by bFGF. Further investigations with HT-29 cells indicated that P7 arrested the cell cycle at the G0/G1 phase of bFGF-stimulated cells, reduced the levels of phospho-Erk1/Erk2 induced by bFGF, and caused significant changes in the expression of proteins related to proliferation, cell cycle, and cancer. Our results suggested that the bFGF-binding peptide has a potential antitumor effect on colon cancer. © 2010 Japanese Cancer Association.

Cite

CITATION STYLE

APA

Wang, C., Lin, S., Nie, Y., Jia, X., Wang, J., Xiao, J., … Wu, X. (2010). Mechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells. Cancer Science, 101(5), 1212–1218. https://doi.org/10.1111/j.1349-7006.2010.01501.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free